Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up and T Cell Characteristics of Patients with ASXL1 -Mutated Relapsed or Refractory MDS or CMML Treated with Guadecitabine and Atezolizumab

Casey L. O'Connell, Maria R. Baer, Vu H. Duong, Andreas Due Ørskov, Jakob Werner Hansen, Sunil Kumar Saini, Denice Tsao-Wei, Justin Cheng, Peter A. Jones, Kirsten Grønbæk

Blood (2023) 142 (Supplement 1): 1883.

https://doi.org/10.1182/blood-2023-189486

Published: 2023

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Analysis of ASXL1 Mutated T Cells in Patients with Myeloid Malignancies

Eduardo Fernandez, Jesse Sanchez, Gangning Liang, Mateusz Pospiech, Hongtao Li, Zarko Manojlovic, Houda Alachkar, Casey L. O'Connell

Blood (2023) 142 (Supplement 1): 6453.

https://doi.org/10.1182/blood-2023-173451

Published: 2023

Journal Articles

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Chen Zhang, Douglas Tremblay, John Magnotti, Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew Kuykendall, Casey L. O'Connell, Angela G Fleischman, Ruben Mesa, Abdulraheem Yacoub, John Mascarenhas, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 9693–9695.

https://doi.org/10.1182/blood-2022-157873

Published: 2022

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

Journal Articles

Clinicopathological Features of Isolated Thrombocytopenia Associated with SRSF2 Mutations: A Case Series

Nneka Nwachukwu, Casey L. O'Connell, Maria Vergara-Lluri, Ashley Hagiya, Caitlin O'Neill

Blood (2022) 140 (Supplement 1): 11412–11413.

https://doi.org/10.1182/blood-2022-170439

Published: 2022

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

Gabriel N. Mannis, Elizabeth A. Griffiths, Michael R. Savona, Olatoyosi Odenike, Gail J. Roboz, Casey L. O'Connell, Jacqueline Dillingham, Prieya Wason, Lixia Zhu, Danna Chan, Harold N. Keer, Aram Oganesian, Kim-Hien Dao, Courtney D. DiNardo

Blood (2021) 138 (Supplement 1): 1245.

https://doi.org/10.1182/blood-2021-146264

Published: 2021

Journal Articles

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Blood (2021) 138 (Supplement 1): 66.

https://doi.org/10.1182/blood-2021-144648

Published: 2021

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Blood (2021) 138 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2021-147769

Published: 2021

Journal Articles

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Blood (2021) 138 (Supplement 1): 3682.

https://doi.org/10.1182/blood-2021-154179

Published: 2021

Journal Articles

European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database

Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew T. Kuykendall, Casey L. O'Connell, Jamile M. Shammo, Angela Fleischman, Ruben A. Mesa, Abdulraheem Yacoub, Ronald Hoffman, Erin Moshier, Nicole Zubizarreta, John Mascarenhas

Blood (2021) 138 (Supplement 1): 240.

https://doi.org/10.1182/blood-2021-148020

Published: 2021

Journal Articles

Improving Understanding of MDS Using an Animated Patient's Guide to Benefit Patient Health Outcomes

David A. Sallman, MD, Tracey Iraca, Casey L. O'Connell, MD, Rafael Bejar, MD PhD, Sandra Kurtin, ANP

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134647

Published: 2020

Journal Articles

Clinical Features of Idiopathic Erythrocytosis in a Racially Diverse Population

Caitlin O'Neill, MD, Ah-Reum Jeong, MD, Ibrahim Syed, Casey L. O'Connell, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141372

Published: 2020

Journal Articles

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19

Lantarima Bhoopat, MD, Anastasia Martynova, MD, April Choi, MD, Pattharawin Pattharanitima, MD, Semi Han, MD, Senxi Du, Ibrahim Syed, Catherine Chan, PharmD, Caitlin O'Neill, MD, Esther Oh, PharmD, Casey L. O'Connell, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-141732

Published: 2020

Journal Articles

A Pilot/Safety Study of sEphB4-Hsa in Combination with a Hypomethylating Agent for Patients with Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Previously Treated with a Hypomethylating Agent

Caitlin O'Neill, MD, Akil Merchant, MD, Parkash S. Gill, MD, Casey L. O'Connell, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141340

Published: 2020

Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133855

Published: 2020

Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Blood (2019) 134 (Supplement_1): 846.

https://doi.org/10.1182/blood-2019-122980

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Michael R. Savona, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Katherine J. Walsh, MD, Raoul Tibes, MD PhD, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Nikolai A. Podoltsev, MD PhD, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 2957.

https://doi.org/10.1182/blood-2019-129962

Published: 2019

NARROW

Long-Term Follow-up and T Cell Characteristics of Patients with ASXL1 -Mutated Relapsed or Refractory MDS or CMML Treated with Guadecitabine and Atezolizumab

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Analysis of ASXL1 Mutated T Cells in Patients with Myeloid Malignancies

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Clinicopathological Features of Isolated Thrombocytopenia Associated with SRSF2 Mutations: A Case Series

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database

Improving Understanding of MDS Using an Animated Patient's Guide to Benefit Patient Health Outcomes

Clinical Features of Idiopathic Erythrocytosis in a Racially Diverse Population

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19

A Pilot/Safety Study of sEphB4-Hsa in Combination with a Hypomethylating Agent for Patients with Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Previously Treated with a Hypomethylating Agent

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only